Back
Intellia Therapeutics 10K Form
Sell
20
NTLA
Intellia Therapeutics
Last Price:
21.83
Seasonality Move:
34.64%
7 Day Trial
ALL ACCESS PASS
$
7
Key Filings
10K form not available
Receive NTLA News And Ratings
See the #1 stock for the next 7 days that we like better than NTLA
NTLA Financial Statistics
Sales & Book Value
Annual Sales: | $36.28M |
---|---|
Cash Flow: | $-94.57M |
Price / Cash Flow: | 0 |
Annual Sales: | $11.29 |
Price / Book: | 2 |
Profitability
EPS (TTM): | -5.41000 |
---|---|
Net Income (TTM): | $-481.19M |
Gross Margin: | -- |
Return on Equity: | -42.82% |
Return on Assets: | -35.35% |
Intellia Therapeutics Earnings Forecast
Key Intellia Therapeutics Financial Ratios
- The Research & Development expenses have been 1,199.36% of Revenue.
- The Net Earning history of NTLA is -1,326.51% of Total Revenues.
- Per Share Earnings over the last 9 years have been positive in 1 years.
Intellia Therapeutics Stock Price Chart
Industry, Sector and Symbol
Stock Exchange: | NASDAQ |
---|---|
Current Symbol: | NTLA |
CUSIP: | 45826J |
Website: | intelliatx.com |
Debt
Debt-to-Equity Ratio: | 0 |
---|---|
Current Ratio: | 8.67 |
Quick Ratio: | 8.23 |
Price-to-Earnings
Trailing P/E Ratio: | 0 |
---|---|
Forward P/E Ratio: | 0 |
NTLA Technical Analysis vs Fundamental Analysis
Sell
20
Intellia Therapeutics (NTLA)
is a Sell
Is Intellia Therapeutics a Buy or a Sell?
-
Intellia Therapeutics stock is rated a Sell
The current Intellia Therapeutics [NTLA] share price is $21.80. The Score for NTLA is 20, which is 60% below its historic median score of 50, and infers higher risk than normal.